Johnson & Johnson quarter earnings

Note: This section contains information in English only.
Source: Dukascopy Bank SA
Johnson & Johnson delivered strong first-quarter results, highlighting the strength of its diversified business model. The company reported total sales of $21.9 billion, a 2.4% increase compared to the same period last year. Net earnings surged to $11 billion, up 238%, driven in part by a one-time gain. Adjusted earnings per share rose 2.2% to $2.77, while free cash flow reached approximately $3.4 billion. In terms of business segments, Innovative Medicine saw 4.2% operational growth, led by strong sales of cancer, immunology, and neuroscience treatments. The MedTech segment grew 4.1% operationally, supported by sales in cardiovascular devices (Abiomed) and surgical tools, though orthopedic products showed some weakness.



Regionally, U.S. sales increased by 5.9%, reflecting solid domestic performance. International sales declined 1.8% but rose 2.1% when adjusting for currency impacts. J&J also made key advancements in innovation this quarter, including progress with TREMFYA in inflammatory bowel disease, RYBREVANT + LAZCLUZE in lung cancer, and its new robotic surgery system OTTAVA. The company also strengthened its neuroscience portfolio by completing the acquisition of Intra-Cellular Therapies. Looking ahead, Johnson & Johnson remains confident in its full-year 2025 guidance. However, the company did not provide GAAP forecasts due to uncertainty around legal matters and acquisition-related costs.
Back to articles

Actual Topics

Wed, 23 Apr 2025 12:14:47 GMT

Philip Morris quarter earnings

Philip Morris International reported strong Q1 2025 results, driven by growth in smoke-free products. Smoke-free products like IQOS and ZYN made up 42% of total revenue, with net revenue up 20% and gross profit up 33%. These products are now available in 95 markets. IQOS continued to gain market share in Japan and Europe, while ZYN nicotine pouches grew 53%

Tue, 15 Apr 2025 09:40:59 GMT

BlackRock, Inc. quarter earnings

In the most recent quarter, the firm reported $84 billion in total net inflows, representing 3% annualized organic asset growth. This was driven by a record first quarter for iShares® ETFs, alongside strong inflows into private markets and active strategies. Revenue increased 12% year-over-year, reflecting the positive impact of market appreciation, organic base fee growth, and fees related to the GIP

Subscribe to "Fundamental Analysis" feed

Subscribe
To learn more about Dukascopy Bank CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
For further information regarding potential cooperation,
please call us or make callback request.
To learn more about Dukascopy Bank Binary Options / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
Chcete-li se dozvědět více o platformě Dukascopy Bank CFD / Forex, SWFX a dalších souvisejících obchodních informacích, prosím, zavolejte nám, nebo vám můžeme zavolat my.
To learn more about Crypto Trading / CFD / Forex trading platform, SWFX and other trading related information,
please call us or make callback request.
To learn more about Business Introducer and other trading related information,
please call us or make callback request.
For further information regarding potential cooperation,
please call us or make callback request.